Form 4: MaxCyte Director John Johnston Executes Option and Sells Shares Under 10b5-1 Plan

Director John Johnston exercised stock options and sold shares of MaxCyte, Inc. under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On September 26, 2024, John Johnston, a director of MaxCyte, Inc., exercised stock options to acquire 3,000 shares of common stock at a price of $2.926 per share.
• Simultaneously, Johnston sold 3,000 shares of MaxCyte common stock at a weighted average price of $3.82, with individual sales prices ranging from $3.80 to $3.87.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on December 19, 2023.
• Following these transactions, Johnston directly owns 141,950 shares of MaxCyte common stock and holds options for 4,396 shares.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing insider transactions, which is neutral in sentiment.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The use of a 10b5-1 trading plan indicates that the transactions were pre-planned and not based on any material non-public information.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates